PureTech Takes On Roche With Improved IPF Drug

Modified Version Of Esbriet Seems Safer

06 Jan 2022

• By Ayisha Sharma

The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.

Squiggly lines from start to finish line, a straight line from start to finish underneath. Streamlined concept. — PureTech Hopes To Piggyback Off Esbriet Data For A Smoother Filing • Source: Alamy

PureTech Health plc will start a dose-ranging study of LYT-100, a modified version of Roche Holding AG’s idiopathic pulmonary fibrosis (IPF) blockbuster Esbriet as part of its plan to advance the candidate into registrational development via a simplified US regulatory pathway.

The announcement came as data from a Phase I trial in 49 healthy adults aged between 60 and 79 showed that 38% fewer people on LYT-100 experienced adverse events than...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

29 May 2025

• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.